Saline placebo for pembrolizumab

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Non-small Cell Lung Cancer

Phase 3

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)

CompletedNCT02775435

Merck Sharp & Dohme LLCNon-small Cell Lung Cancer

Start: 2016-06-09End: 2023-09-14Updated: 2024-10-08

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study

CompletedNCT03875092

Merck Sharp & Dohme LLCNon-small Cell Lung Cancer

Start: 2017-04-21End: 2023-09-14Updated: 2024-10-01

Related Papers

Impact on overall survival after adjusting for treatment crossover in first-line metastatic NSCLC trials for pembrolizumab plus chemotherapy.

Journal of Clinical Oncology2026-05-28

Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer.

2025-06-11

Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up

Journal of Thoracic Oncology2024-04-1834 citations

Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small<scp>‐</scp>cell lung cancer in KEYNOTE‐407

Cancer Science2023-05-1512 citations

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

Journal of Clinical Oncology2023-02-03430 citations

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC.

2022-11-0826 citations

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407.

2021-09-2532 citations

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Cancer2020-09-11107 citations

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.

2020-06-26471 citations

Pembrolizumab Plus Chemo for Advanced Non-Small Cell Lung Cancer

Oncology Times2019-11-14

Progression free survival (PFS) benefits of immuno-oncology agents (IOs) and implications for market cost-sharing inefficiencies.

Journal of Clinical Oncology2019-05-20

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

New England Journal of Medicine2018-09-253532 citations

Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2018-05-20121 citations